# Landos Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/landos-biopharma

- Industry: Pharmaceuticals
- Headquarters: Blacksburg, US
- Website: www.landosbiopharma.com
- Total disclosed funding: $70M
- Latest round: Series B (Aug 9, 2019)
- Investors on record: 4

## About

Based in Virginia, US, and founded in 2017 Landos Biopharma, Inc. is a biopharmaceutical company that develops oral therapeutics for patients with autoimmune diseases. The company has approximately 33 employees and has raised a total of USD 70 million in 2 venture funding rounds.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The LANCE platform identifies novel therapeutic targets based on predictions of metabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need.

The company’s revenue is generated through the sale of its products to hospitals.

Landos Biopharma, Inc. expects to initiate a Phase 2 trial in patients affected by moderate to severe CD in the first half of 2021.

## Funding rounds

- Series B, Aug 9, 2019, $60M — OUP (Osage University Partners), PBM Capital Group, RTW Investments, Perceptive Advisors
- Series A, Sep 21, 2017, $10M — Perceptive Advisors

## Investors

- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A, Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B
- PBM Capital Group (https://capitalatlas.ai/funds/pbm-capital-group) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B